Novartis, working to improve Alcon, gives back ThromboGenics drug Jetrea
admin 18th September 2017 Uncategorised 0Novartis, which has been trying to fix its struggling Alcon eye unit, figures that process will be easier without a floundering eye medication in the portfolio. Accordingly, it has returned the rights to Jetrea to ThromboGenics.
More: Novartis, working to improve Alcon, gives back ThromboGenics drug Jetrea
Source: fierce